Article

Clonal expansion of personalized anti-tumor T cells from circulation using tumor organoid-immune co-cultures

2020-11-08

Abstract excerpt

Tumor-specific cytotoxic T cells are effective tools for cancer immunotherapy, but the ability to generate them continues to be a challenge. Furthermore, there are no compelling approaches to empirically identify tumor-targeting T cells and T cell receptors by exploiting the multitude of antigens on tumor cell surfaces. Here, we use patients’ peripheral blood and autologous tumor organoids to enrich tumor-specific...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 96f0dc9d-1f5b-548d-8d84-76146f89be34
DOI: 10.1101/2020.11.06.371807

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clonal expansion of personalized anti-tumor T cells from circulation using tumor organoid-immune co-culturesDOI 10.1101/2020.11.06.371807Read

Identification and validation of tumor-specific T cell receptors from tumor infiltrating lymphocytes using tumor organoid co-culturesSemantic proximity Read

Organoid-T cell co-cultures functionally stratify tumor-reactive T cells and their responses to immune checkpoint inhibitorsSemantic proximity Read

Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid applicationSemantic proximity Read

Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes.Semantic proximity Read

Engineering chimeric antigen receptor-T cells for cancer treatment.Semantic proximity Read

Engineering the Immune Microenvironment into Organoid ModelsSemantic proximity Read

Advances in identification and selection of personalized neoantigen/T-cell pairs for autologous adoptive T cell therapiesSemantic proximity Read

Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells.Semantic proximity Read

Enhancing Patient Lymphocyte Response to Peritoneal Malignancies Using a Personalized Immunocompetent Microfluidic Co-Culture PlatformSemantic proximity Read

A Peptide-Based Neoantigen Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard TreatmentSemantic proximity Read

Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes.Semantic proximity Read

Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients.Semantic proximity Read